1. 1. Erek E, Süleymanlar G. Böbreğin Yapısı Fonksiyonları. İliçin G, Biberoğlu K, Süleymanlar G, Ünal S. İç Hastalıkları.2. baskı. Ankara: Güneş Kitabevi, 2003:1211-1228.2. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access 2000 Update. New York, National Kidney Foundation, 2007
2. 5: 395-403.4. Delanty N, Vaughan CJ. Vascular effects of statin in stroke. Stroke 1997,28:1-15.5. Vernaglione L, Cristofano C, Muscogiuri P, BSc and Chimienti S. Does atorvastatin influence serum C-Reactive Protein levels in patients on long- term hemodialysis? Am J Kidney Dis Vol: 43 No: 3 2004 pp. 471-478.6. . El Nahas M. Progression of Chronic Renal Failure. In: Comprehensive Clinical Nephrology. Johnson R, Feehally J (eds). London, Mosby 2000: 67-71.7. Gruskin AB, Baluarte HJ, Dabbagh Shermine. Hemodialysis and Peritoneal Dialysis In: Pediatric Kidney Disease. Edelmann CM (ed). Second Edition, Boston, Little, Brown and Company,1992: 827-916.8. National Kidney Foundation. K/DOQI clinical practice guidelines for vascular access, update 2006. Am J Kidney Dis 2006
3. 48 (1): 176-247.9. O'Rıordan E, Chen J, Brodsky SV, Smirnova I, Lı H, Goligorsky MS. Endothelial cell dysfunction: The syndrome in making. Kidney Int. 2005;67:1654-165810. Guldener CV, Janssen MJFM, Lambert J, Steyn M, Donker AJM, Stehouwer CDA. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998;13:1782-178611. Yılmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C.The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006Jan;47(1):42-5012. Yılmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Aydin A,Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005 Dec 27;80(12):1660-613. Aviram M, Rosenblat M, Bisgaier CL, et al. 1998 Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants againts lipoprotein oxidation. Atherosclerosis 138:271-280.14. Fuhrman B, Koren L, Volkova N, et al. 2002 Atorvastatin therapy in hypercholesterolemic patients supresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164:179-185.15. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003
4. 41: 565-570.16. Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M : Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol 90: 942-946, 2002.17. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17 : 1513-1517, 2002.18. Treasure CB, Klein JL, Weintraub WS, Talley JD, et al. 1995 Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Eng J Med 332:481-487.19. Kuruishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K 2000 The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:1004-101020. .Parekh RS, Gidding SS. Cardiovascular complications in pediatric end-stage renal disease. Pediatr Nephrol 2005
5. 1. Erek E, Süleymanlar G. Böbreğin Yapısı Fonksiyonları. İliçin G, Biberoğlu K, Süleymanlar G, Ünal S. İç Hastalıkları.2. baskı. Ankara: Güneş Kitabevi, 2003:1211-1228.2. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access 2000 Update. New York, National Kidney Foundation, 2007; 944; 117-1213. Austin MA, Hokanson JE, Brunzell JD. Characterization of low density lipoprotein subclasses: methodologic appoaches and clinical relevance. Curr Opin Lipidol 1994; 5: 395-403.4. Delanty N, Vaughan CJ. Vascular effects of statin in stroke. Stroke 1997,28:1-15.5. Vernaglione L, Cristofano C, Muscogiuri P, BSc and Chimienti S. Does atorvastatin influence serum C-Reactive Protein levels in patients on long- term hemodialysis? Am J Kidney Dis Vol: 43 No: 3 2004 pp. 471-478.6. . El Nahas M. Progression of Chronic Renal Failure. In: Comprehensive Clinical Nephrology. Johnson R, Feehally J